Reuters logo
5 months ago
BRIEF-Taigen Biopharmaceuticals Holdings says positive result of phase two clinical trial of anti-hepatitis C virus new drug TG-2349
February 9, 2017 / 7:53 AM / 5 months ago

BRIEF-Taigen Biopharmaceuticals Holdings says positive result of phase two clinical trial of anti-hepatitis C virus new drug TG-2349

1 Min Read

Feb 9 (Reuters) - Taigen Biopharmaceuticals Holdings Ltd :

* Says positive result of phase two clinical trial of anti-hepatitis C virus new drug TG-2349

Source text in Chinese: goo.gl/sWa1nM

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below